Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-07-21 00:00:00 ET · period of report 2022-07-21 · accession 0000899243-22-026519 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-07-21 | 2022-07-21 | KLRS | Hallal David | Dir, 10% | S - Sale | $5.33 | -4,227 | 2.07M | -0.2% | -$22.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-21 | S | D | 4,227 | $5.33 | 2,073,662 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.26 to $5.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |